Press Releases

June 24, 2021
Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1
June 10, 2021
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
June 2, 2021
Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
May 18, 2021
Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
May 10, 2021
Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress
May 3, 2021
Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
April 21, 2021
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors
March 11, 2021
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
March 9, 2021
Revolution Medicines to Participate in Upcoming Investor Conferences
March 2, 2021
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress